Old Well Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Old Well Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,208	Closed	-$257K	–	35
2023 Q4	$257K	Buy	+8,208	New	+$196K	0.23%	34

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Old Well Partners's ACAD Position: Q1 2024 in Review

Old Well Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 8,208 shares — an estimated $257K sold.

Old Well Partners first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $257K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Old Well Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Old Well Partners sold 8,208 Acadia Pharmaceuticals shares in Q1 2024, an estimated $257K.
Old Well Partners first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Old Well Partners's Acadia Pharmaceuticals position peaked at $257K in Q4 2023.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Old Well Partners's 13F filing for Q1 2024, filed 15 May 2024.